As of Jul 27
| -0.024 / -2.40%|
The 3 analysts offering 12-month price forecasts for ContraVir Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 4.00. The median estimate represents a +412.30% increase from the last price of 0.98.
The current consensus among 3 polled investment analysts is to Buy stock in ContraVir Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.